Opinion leaders of CD society getting together in Budapest
In the recent two weeks, Cyclolab had the pleasure to welcome two prominent pioneers of cyclodextrin research, Prof. Loftsson from
Category: Pharma applications
Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery
In the laboratory of C. M. O’Driscoll (University College Cork), an antibody targeted cyclodextrin-based siRNA delivery vector (CD.DSPE-PEGFab) was developed
NO-releasing cyclodextrins
Nitric oxide (NO) is a signaling molecule produced by almost all types of organisms ranging from bacteria to plants and
Mannose with anti-cancer effect
In a recently published Nature report it was investigated how tumor cells respond to different forms of sugar [1]. It
Cyclodextrins involved in clinical trials to start
According to clinicaltrials.gov, currently, there are 14 cyclodextrin-related clinical trials that in the status of i) Not yet recruiting, ii)
Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 in Support of Benefit-Risk Profile of ZULRESSO™ (brexanolone) Injection for Treatment of Postpartum Depression
If approved, ZULRESSO would be the first medicine specifically indicated for the treatment of postpartum depression (PPD) Sage Therapeutics (NASDAQ:
Melinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, announced positive
HPBCD treatment for Niemann-Pick C: Mallinckrodt communicated results of clinical trial
Mallinckrodt Pharmaceuticals recently revealed findings of their completed registration trial for VTS-270 (Hydroxypropyl Betadex- HPBCD), a development product to treat
New Clinical Trial for Efficacy and Safety of Sugammadex in 0-2 Years Old Children
Federal Research Institute of Pediatric Hematology, Oncology and Immunology is about to launch a clinical study at Dmitry Rogachev National
Minimizing tissue reactions with cyclodextrins at infusion site of insulin therapy
A recently published patent application of Cell and Molecular Tissue Engineering LLC (WO2017180708) discloses a method of lowering the concentrations of